

Liang Chen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1101095/liang-chen-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

55
papers

5,315
citations

25
h-index

58
g-index

58
ext. papers

6,089
ext. citations

11.5
avg, IF

4.53
L-index

#	Paper	IF	Citations
55	Pharmaceutical applications of framework nucleic acids.. <i>Acta Pharmaceutica Sinica B</i> , 2022 , 12, 76-91	15.5	4
54	Strategies for developing PD-1 inhibitors and future directions. <i>Biochemical Pharmacology</i> , 2022 , 202, 115113	6	0
53	A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC. <i>EMBO Molecular Medicine</i> , 2021 , e14296	12	1
52	Urinary malate dehydrogenase 2 is a new biomarker for early detection of non-small-cell lung cancer. <i>Cancer Science</i> , 2021 , 112, 2349-2360	6.9	7
51	Phase separation of EML4-ALK in firing downstream signaling and promoting lung tumorigenesis. <i>Cell Discovery</i> , 2021 , 7, 33	22.3	10
50	Targeting hyperactive TGFBR2 for treating MYOCD deficient lung cancer. <i>Theranostics</i> , 2021 , 11, 6592-6606	6.6	0
49	Intrinsic bioactivity of black phosphorus nanomaterials on mitotic centrosome destabilization through suppression of PLK1 kinase. <i>Nature Nanotechnology</i> , 2021 , 16, 1150-1160	28.7	15
48	Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer.. <i>EMBO Molecular Medicine</i> , 2021 , e14502	12	0
47	Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors. <i>EMBO Molecular Medicine</i> , 2020 , 12, e11571	12	13
46	GATA6 Exerts Potent Lung Cancer Suppressive Function by Inducing Cell Senescence. <i>Frontiers in Oncology</i> , 2020 , 10, 824	5.3	4
45	Systematic identification of CDC34 that functions to stabilize EGFR and promote lung carcinogenesis. <i>EBioMedicine</i> , 2020 , 53, 102689	8.8	6
44	Discovery of Novel Inhibitor for WNT/ β Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual Screening. <i>Molecules</i> , 2020 , 25,	4.8	7
43	A tumor suppressor enhancing module orchestrated by GATA4 denotes a therapeutic opportunity for GATA4 deficient HCC patients. <i>Theranostics</i> , 2020 , 10, 484-497	12.1	9
42	Inactivation of tumor suppressor gene Clusterin leads to hyperactivation of TAK1-NF- κ B signaling axis in lung cancer cells and denotes a therapeutic opportunity. <i>Theranostics</i> , 2020 , 10, 11520-11534	12.1	7
41	Challenges to the Standardization of Trauma Data Collection in Burn, Traumatic Brain Injury, Spinal Cord Injury, and Other Trauma Populations: A Call for Common Data Elements for Acute and Longitudinal Trauma Databases. <i>Archives of Physical Medicine and Rehabilitation</i> , 2019 , 100, 891-898	2.8	2
40	Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition. <i>Nature Communications</i> , 2019 , 10, 1665	17.4	25
39	Identification of Germline Mismatch Repair Gene Mutations in Lung Cancer Patients With Paired Tumor-Normal Next Generation Sequencing: A Retrospective Study. <i>Frontiers in Oncology</i> , 2019 , 9, 550	5.3	14

38	IRF8 induces senescence of lung cancer cells to exert its tumor suppressive function. <i>Cell Cycle</i> , 2019 , 18, 3300-3312	4.7	5
37	FOXM1c promotes oesophageal cancer metastasis by transcriptionally regulating IRF1 expression. <i>Cell Proliferation</i> , 2019 , 52, e12553	7.9	12
36	Loss of hypermethylated in cancer 1 (HIC1) promotes lung cancer progression. <i>Cellular Signalling</i> , 2019 , 53, 162-169	4.9	3
35	In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E3978-E3986	11.5	45
34	A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo. <i>Nature Biotechnology</i> , 2018 , 36, 258-264	44.5	702
33	The Development and Validity of the Adult Burn Outcome Questionnaire Short Form. <i>Journal of Burn Care and Research</i> , 2018 , 39, 771-779	0.8	3
32	Challenges to the Standardization of Burn Data Collection: A Call for Common Data Elements for Burn Care. <i>Journal of Burn Care and Research</i> , 2018 , 39, 201-208	0.8	6
31	Direct induction of neural progenitor cells transiently passes through a partially reprogrammed state. <i>Biomaterials</i> , 2017 , 119, 53-67	15.6	6
30	In vitro evaluation of electrospun silk fibroin/nano-hydroxyapatite/BMP-2 scaffolds for bone regeneration. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2017 , 28, 257-270	3.5	27
29	Mup-knockout mice generated through CRISPR/Cas9-mediated deletion for use in urinary protein analysis. <i>Acta Biochimica Et Biophysica Sinica</i> , 2016 , 48, 468-73	2.8	4
28	Preparation of collagen/hydroxyapatite/alendronate hybrid hydrogels as potential scaffolds for bone regeneration. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016 , 143, 81-87	6	64
27	Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation. <i>Oncotarget</i> , 2016 , 7, 69760-69769	3.69	33
26	The impact of the MYB-NFIB fusion proto-oncogene in vivo. <i>Oncotarget</i> , 2016 , 7, 31681-8	3.3	7
25	EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment. <i>Oncotarget</i> , 2016 , 7, 3367-78	3.3	8
24	Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer. <i>Oncotarget</i> , 2016 , 7, 3884-96	3.3	25
23	Identification of urine protein biomarkers with the potential for early detection of lung cancer. <i>Scientific Reports</i> , 2015 , 5, 11805	4.9	29
22	Efficient Generation of Mice with Consistent Transgene Expression by FEEST. <i>Scientific Reports</i> , 2015 , 5, 16284	4.9	2
21	Phosphorylation of mutationally introduced tyrosine in the activation loop of HER2 confers gain-of-function activity. <i>PLoS ONE</i> , 2015 , 10, e0123623	3.7	6

20	lbrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells. <i>Oncotarget</i> , 2015 , 6, 31313-22	3.3	32
19	Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor. <i>Oncotarget</i> , 2015 , 6, 31628-39	3.3	2
18	Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. <i>Clinical Cancer Research</i> , 2014 , 20, 1204-1211	12.9	49
17	Transcriptomic characterization of hepatocellular carcinoma with CTNNB1 mutation. <i>PLoS ONE</i> , 2014 , 9, e95307	3.7	32
16	Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. <i>Cancer Research</i> , 2013 , 73, 6770-9	10.1	61
15	Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 8699-704	11.5	103
14	Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 4973-85	12.9	115
13	A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in lupus-prone NZB/NZW F1 and MRL/lpr mice. <i>Journal of Immunology</i> , 2011 , 186, 527-38	5.3	106
12	HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 474-9	11.5	141
11	Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. <i>Nature</i> , 2009 , 462, 1070-4	50.4	766
10	Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. <i>Nature Medicine</i> , 2008 , 14, 1351-6	50.5	1121
9	Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. <i>Clinical Cancer Research</i> , 2008 , 14, 6478-86	12.9	67
8	Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer. <i>Carcinogenesis</i> , 2008 , 29, 747-53	4.6	40
7	JNK2 negatively regulates CD8+ T cell effector function and anti-tumor immune response. <i>European Journal of Immunology</i> , 2007 , 37, 818-29	6.1	20
6	LKB1 modulates lung cancer differentiation and metastasis. <i>Nature</i> , 2007 , 448, 807-10	50.4	774
5	Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. <i>Cancer Cell</i> , 2007 , 12, 81-93	24.3	193
4	Epigenetic and transcriptional programs lead to default IFN-gamma production by gammadelta T cells. <i>Journal of Immunology</i> , 2007 , 178, 2730-6	5.3	50
3	Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. <i>Cancer Research</i> , 2007 , 67, 4933-9	10.1	134

- 2 The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. *Cancer Cell*, **2006**, 9, 485-95 24.3 389
- 1 The inhibition of lung cancer cell growth by intracellular immunization with LC-1 ScFv. *Cell Research*, **2002**, 12, 47-54 24.7 9